Mario Bargetzi

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

Monique Terwijn, Wim L.J. van Putten, Angèle Kelder et al. · Journal of Clinical Oncology · 2013 · 449 citations · Full text

Medicine, Hematology, Oncology +16

Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4

Mario Bargetzi, Toshifumi Aoyama, Frank J. Gonzalez et al. · Clinical Pharmacology & Therapeutics · 1989 · 264 citations

Medicine, Biochemistry, Pharmacology +17

A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis

Heiko Witt, Miklós Sahin‐Tóth, Olfert Landt et al. · Nature Genetics · 2006 · 251 citations · Full text

Medicine, Biochemistry, Molecular Biology +8

Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)

Michele Ghielmini, Shu‐Fang Hsu Schmitz, Sergio Cogliatti et al. · Journal of Clinical Oncology · 2004 · 197 citations · Full text

Medicine, Hematology, Pharmacotherapy +12

Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)

Christoph Mamot, Dirk Klingbiel, Felicitas Hitz et al. · Journal of Clinical Oncology · 2015 · 189 citations

Medicine, Nuclear Medicine, Oncology +16